Limits...
Protective effect of resveratrol against pressure overload-induced heart failure.

Gupta PK, DiPette DJ, Supowit SC - Food Sci Nutr (2014)

Bottom Line: Likewise, the TAC protocol increased markers of oxidative stress, cardiac hypertrophy, inflammation, fibrosis, hypoxia, and apoptosis.These pathological changes were significantly attenuated by resveratrol treatment.Resveratrol treatment significantly attenuates the adverse cardiac remodeling and dysfunction produced by the TAC protocol in C57/BL6 mice and this activity is mediated, at least in part, by the inhibition of oxidative stress and inflammation indicating a therapeutic potential of resveratrol in HF.

View Article: PubMed Central - PubMed

Affiliation: Department of Cell Biology & Anatomy, University of South Carolina School of Medicine Columbia, South Carolina.

ABSTRACT
Transverse aortic constriction (TAC)-induced pressure overload (PO) causes adverse cardiac remodeling and dysfunction that progresses to heart failure (HF). The purpose of this study was to determine whether the potent antioxidant, resveratrol, significantly attenuates PO-induced HF in wild-type mice. Male C57BL6 mice were subjected to either sham or TAC surgery. One group of TAC mice was given daily resveratrol treatment. Echocardiographic, biometric, and immunohistological analyses were performed on the three groups of mice. All echocardiographic parameters demonstrated significantly greater adverse cardiac remodeling and dysfunction in the TAC compared to the sham mice. Increases in the ratios of heart weight (HW)/body weight (BW) and lung weight (LW)/BW and a sharp decline in the percentage of ejection fraction and fractional shortening were found in TAC relative to sham mice. Likewise, the TAC protocol increased markers of oxidative stress, cardiac hypertrophy, inflammation, fibrosis, hypoxia, and apoptosis. These pathological changes were significantly attenuated by resveratrol treatment. Resveratrol treatment significantly attenuates the adverse cardiac remodeling and dysfunction produced by the TAC protocol in C57/BL6 mice and this activity is mediated, at least in part, by the inhibition of oxidative stress and inflammation indicating a therapeutic potential of resveratrol in HF.

No MeSH data available.


Related in: MedlinePlus

Resveratrol treatment attenuates the adverse cardiac remodeling and contractile dysfunction in TAC-induced heart failure. Echocardiography was performed at the indicated time points in the sham, TAC, and TAC + resveratrol groups of mice. (A) LVID;d. (B) LVPW;d. (C) EF. (D) FS. Values are expressed as the mean ± SD. *P < 0.05 was considered statistically significant.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4048607&req=5

fig02: Resveratrol treatment attenuates the adverse cardiac remodeling and contractile dysfunction in TAC-induced heart failure. Echocardiography was performed at the indicated time points in the sham, TAC, and TAC + resveratrol groups of mice. (A) LVID;d. (B) LVPW;d. (C) EF. (D) FS. Values are expressed as the mean ± SD. *P < 0.05 was considered statistically significant.

Mentions: After 4 weeks of TAC, LVID;d was significantly increased in TAC mice compared to sham operated. Resveratrol treatment was able to significantly attenuate this increase (Fig. 2A). Similarly, LVPW;d was significantly increased in TAC mice compared to sham-operated mice (Fig. 2B) and significantly attenuated by the resveratrol treatment. As shown in Figure 2C and B. LV systolic function, as assessed by EF (Fig. 2C) and FS (Fig. 2D) was significantly decreased in the TAC mice compared to sham-operated mice. Resveratrol treatment significantly attenuated the sharp decline of both parameters.


Protective effect of resveratrol against pressure overload-induced heart failure.

Gupta PK, DiPette DJ, Supowit SC - Food Sci Nutr (2014)

Resveratrol treatment attenuates the adverse cardiac remodeling and contractile dysfunction in TAC-induced heart failure. Echocardiography was performed at the indicated time points in the sham, TAC, and TAC + resveratrol groups of mice. (A) LVID;d. (B) LVPW;d. (C) EF. (D) FS. Values are expressed as the mean ± SD. *P < 0.05 was considered statistically significant.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4048607&req=5

fig02: Resveratrol treatment attenuates the adverse cardiac remodeling and contractile dysfunction in TAC-induced heart failure. Echocardiography was performed at the indicated time points in the sham, TAC, and TAC + resveratrol groups of mice. (A) LVID;d. (B) LVPW;d. (C) EF. (D) FS. Values are expressed as the mean ± SD. *P < 0.05 was considered statistically significant.
Mentions: After 4 weeks of TAC, LVID;d was significantly increased in TAC mice compared to sham operated. Resveratrol treatment was able to significantly attenuate this increase (Fig. 2A). Similarly, LVPW;d was significantly increased in TAC mice compared to sham-operated mice (Fig. 2B) and significantly attenuated by the resveratrol treatment. As shown in Figure 2C and B. LV systolic function, as assessed by EF (Fig. 2C) and FS (Fig. 2D) was significantly decreased in the TAC mice compared to sham-operated mice. Resveratrol treatment significantly attenuated the sharp decline of both parameters.

Bottom Line: Likewise, the TAC protocol increased markers of oxidative stress, cardiac hypertrophy, inflammation, fibrosis, hypoxia, and apoptosis.These pathological changes were significantly attenuated by resveratrol treatment.Resveratrol treatment significantly attenuates the adverse cardiac remodeling and dysfunction produced by the TAC protocol in C57/BL6 mice and this activity is mediated, at least in part, by the inhibition of oxidative stress and inflammation indicating a therapeutic potential of resveratrol in HF.

View Article: PubMed Central - PubMed

Affiliation: Department of Cell Biology & Anatomy, University of South Carolina School of Medicine Columbia, South Carolina.

ABSTRACT
Transverse aortic constriction (TAC)-induced pressure overload (PO) causes adverse cardiac remodeling and dysfunction that progresses to heart failure (HF). The purpose of this study was to determine whether the potent antioxidant, resveratrol, significantly attenuates PO-induced HF in wild-type mice. Male C57BL6 mice were subjected to either sham or TAC surgery. One group of TAC mice was given daily resveratrol treatment. Echocardiographic, biometric, and immunohistological analyses were performed on the three groups of mice. All echocardiographic parameters demonstrated significantly greater adverse cardiac remodeling and dysfunction in the TAC compared to the sham mice. Increases in the ratios of heart weight (HW)/body weight (BW) and lung weight (LW)/BW and a sharp decline in the percentage of ejection fraction and fractional shortening were found in TAC relative to sham mice. Likewise, the TAC protocol increased markers of oxidative stress, cardiac hypertrophy, inflammation, fibrosis, hypoxia, and apoptosis. These pathological changes were significantly attenuated by resveratrol treatment. Resveratrol treatment significantly attenuates the adverse cardiac remodeling and dysfunction produced by the TAC protocol in C57/BL6 mice and this activity is mediated, at least in part, by the inhibition of oxidative stress and inflammation indicating a therapeutic potential of resveratrol in HF.

No MeSH data available.


Related in: MedlinePlus